Enlivex soars after Israel allows COVID-19 therapy trial
16/08/2021 11:12
** U.S.-listed shares of Israel-based drug developer Enlivex
Therapeutics ENLV.O jump 23% to $12.51 premarket, set for more
than 4-month high
** ENLV said on Sunday Israel's health ministry had allowed
starting a mid-stage clinical trial testing the co's
experimental therapy, Allocetra, in severe and critical COVID-19
patients with acute respiratory distress syndrome urn:newsml:reuters.com:*:nGNX8dv3m8
** Co's trial expected to recruit up to 152 patients and
will assess Allocetra administered with standard of care
treatment
** ENLV up 20.6% YTD, as of last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment